|
ZNF417 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.99360577730113E-15 |
| Normal-vs-Stage2 |
3.38109984454604E-10 |
| Normal-vs-Stage3 |
1.55431223447522E-15 |
| Normal-vs-Stage4 |
1.7412737918221E-12 |
| Stage1-vs-Stage2 |
2.465000E-01 |
| Stage1-vs-Stage3 |
3.937900E-02 |
| Stage1-vs-Stage4 |
4.540500E-03 |
| Stage2-vs-Stage3 |
7.375200E-01 |
| Stage2-vs-Stage4 |
3.523200E-01 |
| Stage3-vs-Stage4 |
4.475800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.027420E-04 |
| Normal-vs-Asian |
1.431100005167E-08 |
| Caucasian-vs-AfricanAmerican |
2.313400E-01 |
| Caucasian-vs-Asian |
5.553400E-01 |
| AfricanAmerican-vs-Asian |
5.052600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.22044604925031E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.328000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.85695903098804E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
2.10831352376317E-13 |
| Normal-vs-Age(81-100Yrs) |
1.923740E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.751010E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.327560E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.633200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.926240E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.886000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.577800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.221100E-04 |
| Classical-VS-Follicular |
1.071560E-02 |
| Classical-VS-Other |
2.816600E-01 |
| Classical-VS-Normal |
6.99979962881514E-10 |
| Tall-VS-Follicular |
2.033000E-01 |
| Tall-VS-Other |
7.326400E-01 |
| Tall-VS-Normal |
2.60347299274599E-13 |
| Follicular-VS-Other |
8.640200E-01 |
| Follicular-VS-Normal |
2.07189820855547E-12 |
| Other-VS-Normal |
8.595500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.66453525910038E-15 |
| Normal-vs-N1 |
3.07049941028481E-11 |
| N0-vs-N1 |
5.729200E-01 |
|
|
